Nucor earnings beat by $0.08, revenue fell short of estimates
EAST HANOVER, N.J. - Novartis (Market Cap: $223.4B), a pharmaceutical giant with robust financial health according to InvestingPro metrics, has announced the FDA approval of Fabhalta (iptacopan) for treating adults with C3 glomerulopathy (C3G), a rare kidney disease. This marks the first authorized treatment specifically for C3G, aimed at reducing proteinuria, a condition of excess protein in urine which is a common symptom of kidney diseases.
Prior to this approval, C3G patients had limited treatment options, mainly focusing on supportive care and broad immunosuppression. Fabhalta, an oral medication, is thought to target the underlying cause of C3G by inhibiting the alternative complement pathway, a part of the immune system implicated in the disease. This development adds to Novartis’s impressive revenue growth of 10.85% and industry-leading gross profit margin of 75.22%.
The approval is based on results from the Phase III APPEAR-C3G study, which demonstrated a significant reduction in proteinuria that was sustained over a one-year period. The study also reported a favorable safety profile for Fabhalta, with the most common adverse reactions being nasopharyngitis and viral infections.
C3G is typically diagnosed in young adults and can progress to kidney failure. The disease is characterized by the buildup of C3 protein in the kidneys, leading to inflammation and damage. Symptoms include fatigue, mobility issues, and mental health challenges such as depression and anxiety.
This is the third U.S. approval for Fabhalta and the second within Novartis’ kidney disease portfolio. Previously, the drug was approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and for patients with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Novartis is also advancing the development of additional therapies for IgAN, including atrasentan and zigakibart, which are in late-stage clinical trials.
The company acknowledges the contributions of patients and investigators in the clinical trials that led to the approval of Fabhalta for C3G. This approval may provide new hope for patients and families affected by this debilitating disease. With a strong financial health score rated as "GREAT" by InvestingPro analysts and current stock price showing potential upside according to Fair Value estimates, Novartis continues to demonstrate its leadership in pharmaceutical innovation and market performance.
The information reported is based on a press release statement from Novartis.
In other recent news, Novartis has announced a significant partnership with the National Football League (NFL), marking the league’s first official collaboration with a pharmaceutical company. This alliance aims to leverage the NFL’s wide audience to enhance health awareness and promote early disease detection, with an initial focus on cancer. The partnership will support the NFL’s Crucial Catch campaign, in collaboration with the American Cancer Society, which emphasizes the importance of cancer awareness and screenings, particularly in underserved communities. Novartis will also serve as the presenting partner for the NFL’s Health and Safety Summit and participate in various league events, such as the Pro Football Hall of Fame Game and the NFL Draft. The collaboration underscores Novartis’ commitment to patient-centered research, with approximately 35 research and development projects in oncology. Victor Bultó, President US of Novartis, highlighted the shared goal of educating and mobilizing communities for early disease detection. Dr. Allen Sills, Chief Medical Officer at the NFL, noted Novartis’ expertise in innovative medicines as a valuable addition to the league’s health initiatives. Tracie Rodburg, Senior Vice President of Sponsorship at the NFL, expressed enthusiasm for the partnership, emphasizing its potential to make a lasting health impact.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.